Antimalarial Agents

Correct Answer

B — 4-aminoquinoline

Rationale

Chloroquine belongs to the 4-aminoquinoline subgroup of quinoline antimalarials, along with hydroxychloroquine. The 8-aminoquinolines are primaquine and tafenoquine. The arylaminoalcohols are quinine and mefloquine. Artemisinins are a structurally distinct class derived from Artemisia annua and are unrelated to the quinoline scaffold.

Correct Answer

C — 8-aminoquinoline

Rationale

Primaquine belongs to the 8-aminoquinoline subgroup, along with tafenoquine. The 4-aminoquinolines are chloroquine and hydroxychloroquine. The arylaminoalcohols are quinine and mefloquine. The 8-aminoquinolines are the only subgroup with activity against hepatic hypnozoites, distinguishing them pharmacologically from all other quinoline subclasses, though that activity is a consequence of their structural classification rather than a requirement for naming the subgroup.

Correct Answer

A — Blood schizonticides

Rationale

Artemisinins are blood schizonticides — they act against intraerythrocytic (blood-stage) parasites. They are not antirelapse agents (a category reserved for 8-aminoquinolines that eliminate hepatic hypnozoites), not suppressive prophylactics (drugs like chloroquine and mefloquine that suppress the erythrocytic cycle for prophylaxis), and not causal prophylactics (drugs like atovaquone-proguanil and doxycycline that kill hepatic schizonts before blood-stage infection). Artemisinins are used for treatment of active blood-stage malaria, not for prophylaxis.

Correct Answer

D — Causal prophylactic

Rationale

Atovaquone-proguanil is a causal prophylactic: it kills hepatic schizonts before they can release merozoites into the bloodstream, preventing blood-stage infection entirely. This causal activity allows it to be stopped shortly after leaving an endemic area rather than continued for several weeks. Suppressive prophylactics (chloroquine, mefloquine) act only on blood-stage parasites. Antirelapse agents (primaquine, tafenoquine) eliminate hepatic hypnozoites. Blood schizonticides (artemisinins, quinine) clear active erythrocytic infection.

Correct Answer

B — Arylaminoalcohol

Rationale

Mefloquine is an arylaminoalcohol, the same structural subgroup as quinine and quinidine. The 4-aminoquinolines are chloroquine and hydroxychloroquine. The 8-aminoquinolines are primaquine and tafenoquine. Artemisinins are a structurally distinct class unrelated to the quinoline scaffold. Recognizing mefloquine as an arylaminoalcohol — and therefore structurally related to quinine — is the classification vocabulary for this drug.

Correct Answer

C — Antirelapse agent

Rationale

Tafenoquine is classified as an antirelapse agent because it eliminates hepatic hypnozoites — the dormant liver-stage parasites responsible for relapse in Plasmodium vivax and Plasmodium ovale infections. Along with primaquine, it is one of only two drugs with this hypnozoite-active classification. It is not a suppressive prophylactic (which acts on blood-stage parasites only), not a blood schizonticide in clinical use, and not an exclusively causal prophylactic.

Correct Answer

A — Inhibition of heme polymerization, causing toxic free heme accumulation in the parasite digestive vacuole

Rationale

Chloroquine is a weak base that concentrates in the acidic digestive vacuole of the Plasmodium trophozoite. There it binds free heme released during hemoglobin digestion and prevents its polymerization into the inert storage form hemozoin. Free heme accumulates to toxic levels, disrupting the parasite membrane and killing the trophozoite. Generation of reactive oxygen species describes the artemisinin mechanism. Mitochondrial electron transport chain inhibition describes atovaquone. Dihydrofolate reductase inhibition describes cycloguanil (the active metabolite of proguanil) and pyrimethamine.

Correct Answer

C — Preferential accumulation of drug in melanin-containing retinal pigment epithelium cells, producing progressive photoreceptor damage

Rationale

Chloroquine and hydroxychloroquine bind avidly to melanin and accumulate to high concentrations in the retinal pigment epithelium, the melanin-rich cell layer that supports the overlying photoreceptors. Sustained drug accumulation in these cells disrupts their function and eventually causes photoreceptor degeneration — producing a characteristic bull's-eye maculopathy on fundoscopic examination. The toxicity is dose- and duration-dependent, progressive, and irreversible once established, which is why regular ophthalmologic screening is required for patients on long-term therapy. The mechanism is not heme polymerization inhibition (which occurs in the parasite digestive vacuole), muscarinic receptor blockade, or nonspecific oxidative damage.

Correct Answer

B — Cleavage of an endoperoxide bridge by ferrous iron, generating carbon-centered free radicals that alkylate parasite proteins

Rationale

Artemisinins contain an endoperoxide bridge that is cleaved by ferrous iron within the parasite digestive vacuole, generating highly reactive carbon-centered free radicals. These radicals alkylate and damage a broad range of parasite proteins and membrane lipids — a multi-target mechanism that is distinct from heme polymerization inhibition (the chloroquine mechanism) and explains why artemisinins retain activity against chloroquine-resistant parasites. Cytochrome bc1 inhibition describes atovaquone. Sequential folate pathway inhibition describes the sulfadoxine-pyrimethamine combination.

Correct Answer

D — A transporter in the parasite digestive vacuole membrane pumps chloroquine out before toxic heme accumulation can occur

Rationale

Chloroquine kills intraerythrocytic Plasmodium parasites by concentrating in the digestive vacuole and binding free heme released during hemoglobin digestion, preventing its polymerization into the inert storage form hemozoin. In resistant Plasmodium falciparum, a mutant digestive vacuole membrane transporter actively pumps chloroquine out of the vacuole before the drug can accumulate to lethal levels. This efflux mechanism is the primary basis of chloroquine resistance and accounts for the widespread treatment failure seen across sub-Saharan Africa, Southeast Asia, and most of South America. The resistance is not based on accelerated hemozoin formation, exclusion of the drug at the red blood cell membrane, or enzymatic drug degradation within the vacuole.

Correct Answer

A — Mefloquine crosses the blood-brain barrier and accumulates in central nervous system tissue

Rationale

Mefloquine crosses the blood-brain barrier and accumulates in central nervous system tissue, producing a neuropsychiatric spectrum ranging from vivid dreams, sleep disturbance, dizziness, and anxiety to severe manifestations including acute psychosis, depression, and seizures. Severe effects can persist for months after discontinuation. The drug is absolutely contraindicated with a personal history of psychiatric illness or seizure disorder. The mechanism is not cholinergic excess, dopamine receptor blockade, or gamma-aminobutyric acid type A activation — those are mechanisms of other drug classes entirely.

Correct Answer

C — Inhibition of the cytochrome bc1 complex of the parasite mitochondrial electron transport chain, collapsing mitochondrial membrane potential

Rationale

Atovaquone inhibits the cytochrome bc1 complex (ubiquinol-cytochrome c reductase) of the Plasmodium mitochondrial electron transport chain. This collapses the mitochondrial membrane potential, which is essential for parasite pyrimidine biosynthesis and survival. The partner drug proguanil acts via its active metabolite cycloguanil, which inhibits dihydrofolate reductase — a complementary second mechanism. Heme polymerization inhibition describes chloroquine. Free radical generation describes artemisinins.

Correct Answer

B — Lumefantrine is a highly lipophilic compound whose oral absorption depends heavily on dietary fat; absorption falls dramatically in the fasted state

Rationale

The food requirement in artemether-lumefantrine is a pharmacokinetic property of lumefantrine specifically. Lumefantrine is highly lipophilic and relies on dietary fat — which stimulates bile salt secretion and forms fat-soluble micelles — to achieve adequate intestinal absorption. In the fasted state, lumefantrine absorption can fall to a small fraction of fed-state levels, leaving inadequate partner drug coverage during the period after the short-lived artemether component has been cleared. This is clinically important: patients who cannot eat (for example, those with severe nausea from malaria) may have inadequate lumefantrine levels even with correct dosing. The food requirement is not related to artemether pharmacokinetics, chemical activation of an endoperoxide bridge (which lumefantrine does not contain), or gastrointestinal tolerability.

Correct Answer

D — Chloroquine acts only on blood-stage parasites and must be continued until all liver-stage parasites have matured into the bloodstream; atovaquone-proguanil kills hepatic schizonts directly, eliminating the liver-stage reservoir

Rationale

The difference in post-travel duration reflects the distinction between suppressive and causal prophylaxis. Chloroquine is a suppressive prophylactic: it acts only on blood-stage (erythrocytic) parasites. Liver-stage parasites are not affected, so chloroquine must be continued for several weeks after leaving the endemic area to cover the period during which any remaining hepatic schizonts mature and release merozoites into the bloodstream, where chloroquine can then act. Atovaquone-proguanil is a causal prophylactic: it kills hepatic schizonts before they release merozoites, eliminating the liver-stage reservoir entirely. Because no liver-stage parasites survive to enter the blood, it can be stopped shortly after leaving the endemic area. The difference is mechanism-based, not related to half-life differences, hepatic accumulation of atovaquone-proguanil, or gametocyte suppression.

Correct Answer

A — Atovaquone-proguanil

Rationale

Atovaquone-proguanil is a causal prophylactic: it kills hepatic schizonts before merozoites are released into the bloodstream, eliminating the liver-stage reservoir. Because no liver-stage parasites survive to mature into the blood, it can be stopped shortly after leaving the endemic area. This is the mechanism-based reason it fits the patient's question. Chloroquine is ineffective in chloroquine-resistant areas and in any case is a suppressive prophylactic requiring weeks of continuation after return. Mefloquine is also a suppressive prophylactic requiring weeks of post-travel continuation. Primaquine is an antirelapse agent used to eliminate hypnozoites in Plasmodium vivax and Plasmodium ovale infections; it is not the preferred first-line prophylactic for a traveler to sub-Saharan Africa with Plasmodium falciparum risk.

Correct Answer

C — Primaquine metabolites generate oxidative stress that cannot be neutralized in glucose-6-phosphate dehydrogenase-deficient red blood cells, causing hemolysis

Rationale

Primaquine is converted by the body to oxidative metabolites that damage red blood cells. In patients with normal glucose-6-phosphate dehydrogenase activity, red blood cells have sufficient antioxidant capacity to neutralize this stress without harm. In glucose-6-phosphate dehydrogenase-deficient red blood cells, that antioxidant defense is absent; oxidative injury causes red blood cell destruction, producing the hemoglobinuria (dark urine) and falling hemoglobin seen in this patient. The severity of hemolysis depends on the degree of enzyme deficiency and the dose of primaquine. This is why glucose-6-phosphate dehydrogenase testing is required before prescribing primaquine or tafenoquine. The hemolysis is not complement-mediated, not related to erythropoietin suppression, and not caused by inhibition of hemoglobin synthesis.

Correct Answer

B — Chloroquine acts only on blood-stage parasites and does not eliminate dormant hypnozoites in the liver, which reactivated to cause relapse

Rationale

Plasmodium vivax forms dormant hypnozoites in hepatocytes that can persist for months to years after the initial infection is cleared. Chloroquine is a blood schizonticide with no activity against liver-stage parasites; it clears the erythrocytic infection but leaves the hypnozoite reservoir intact. Reactivation of hypnozoites produces a true relapse — biologically distinct from reinfection and from recrudescence of surviving blood-stage parasites. Prevention of relapse requires radical cure with an 8-aminoquinoline (primaquine or tafenoquine) to eliminate the hepatic reservoir. The vignette presentation — confirmed Plasmodium vivax with no return travel after eight weeks — is the classic relapse pattern and cannot be explained by chloroquine resistance, inadequate drug metabolism, or reinfection in this context.

Correct Answer

D — Partial artemisinin resistance has emerged in Southeast Asia, in which ring-stage parasites survive peak drug exposure by temporarily reducing their metabolic activity, producing delayed parasite clearance

Rationale

Partial artemisinin resistance is established in the Greater Mekong Subregion, including Cambodia. Resistant ring-stage parasites enter a state of reduced metabolic activity when artemisinin concentrations peak, surviving the brief window of high drug exposure and resuming development when levels fall. The hallmark is delayed parasite clearance — parasites still detectable on day 3 or later despite a full treatment course. When resistance to the partner drug is also present in the same region, the combination loses both active components and clinical treatment failure results, as seen in this vignette. Lumefantrine absorption is fat-dependent but is not population-specific. Artemisinin half-life does not differ by geographic population. Lumefantrine resistance in Plasmodium falciparum does not operate through accelerated hepatic drug metabolism.